Abstract
In patients with type 2 diabetes, a subgroup analysis of a placebo-controlled trial of fenofibrate showed a significant decline in calculated creatinine clearance with fenofibrate. Most fibrates seem to have a detrimental effect on renal function, with the probable exception of gemfibrozil, which is the fibrate of choice in the few situations in which a fibrate is needed.
MeSH terms
-
Creatinine / metabolism*
-
Diabetes Mellitus, Type 2 / drug therapy
-
Fenofibrate / adverse effects*
-
Fenofibrate / therapeutic use
-
Glomerular Filtration Rate
-
Humans
-
Hypolipidemic Agents / adverse effects*
-
Hypolipidemic Agents / therapeutic use
-
Kidney / drug effects
-
Kidney / physiopathology
-
Kidney Function Tests
Substances
-
Hypolipidemic Agents
-
Creatinine
-
Fenofibrate